Genetically modified non-human animals and methods of use thereof
Genetically modified non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome are provided. Also provided are methods for making non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome, and methods for using non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human T cell and/or natural killer (NK) cell development and function, in modeling human pathogen infection of human T cells and/or NK cells, and in various in vivo screens.
1. A genetically modified mouse, comprising:
a null mutation in the mouse SIRPα gene at the mouse SIRPα gene locus and a nucleic acid sequence encoding a human SIRPα protein incorporated into the genome of the genetically modified mouse and operably linked to an endogenous mouse SIRPα gene promoter at the mouse SIRPα gene locus; and
a null mutation in the mouse IL-15 gene at the mouse IL-15 gene locus and a nucleic acid sequence encoding a human IL-15 protein incorporated into the genome of the genetically modified mouse and is operably linked to an endogenous mouse IL-15 gene promoter at the mouse IL-15 gene locus,
wherein the genetically modified mouse expresses the human SIRPα protein and the human IL-15 protein, and
wherein the genetically modified mouse is immunodeficient and comprises a Rag2 gene knock-out and an IL2rg gene knock-out, a Rag2 gene knock-out, or an IL2rg gene knock-out.
2. The genetically modified mouse according to claim 1 , wherein the null mutation is a deletion of at least mouse SIRPα exons 2-4 and wherein the genetically modified mouse is heterozygous for the allele comprising the nucleic acid sequence encoding the human SIRPα protein.
3. The genetically modified mouse according to claim 1 , wherein the null mutation is a deletion of at least mouse SIRPα exons 2-4 and wherein the genetically modified mouse is homozygous for the allele comprising the nucleic acid sequence encoding the human SIRPα protein.
4. The genetically modified mouse according to claim 1 , wherein the human SIRPα protein is a functional fragment of a full length human SIRPα protein.
5. The genetically modified mouse according to claim 4 , wherein the functional fragment comprises an extracellular domain of human SIRPα.
6. The genetically modified mouse according to claim 1 , wherein the human IL-15 protein is a functional fragment of a full-length human IL-15 protein.
7. The genetically modified mouse according to claim 1 , wherein the null mutation is a deletion of at least mouse IL-15 exons 5-8, wherein the genetically modified mouse is heterozygous for the allele comprising the nucleic acid sequence encoding the human IL-15 protein.
8. The genetically modified mouse according to claim 1 , wherein the null mutation is a deletion of at least mouse IL-15 exons 5-8, wherein the genetically modified mouse is homozygous for the allele comprising the nucleic acid sequence that encodes the human IL-15 protein.
9. The genetically modified mouse according to claim 1 , wherein the genetically modified mouse comprises an engraftment of human hematopoietic cells.
10. The genetically modified mouse according to claim 9 , wherein the genetically modified mouse comprises an infection with a human pathogen.
11. The genetically modified mouse according to claim 10 , wherein the human pathogen activates, induces and/or targets T cells.
12. The genetically modified mouse according to claim 10 , wherein the human pathogen activates, induces and/or targets natural killer (NK) cells.
13. The genetically modified mouse according to claim 10 , wherein the human pathogen is a pathogen that infects human intestine or the human lung.
14. An animal engraftment model, comprising a genetically modified mouse comprising:
a null mutation in the mouse SIRPα gene at the mouse SIRPα gene locus and a nucleic acid sequence incorporated into the genome of the genetically modified mouse, which sequence encodes a human SIRPα protein and is operably linked to an endogenous mouse SIRPα gene promoter at the mouse SIRPα gene locus;
a null mutation in the mouse IL-15 gene at the mouse IL-15 gene locus and a nucleic acid sequence incorporated into the genome of the genetically modified mouse, which sequence encodes a human IL-15 protein and is operably linked to an endogenous mouse IL-15 gene promoter at the mouse IL-15 gene locus; and
an engraftment of human hematopoietic cells, wherein the genetically modified mouse (i) expresses the human SIRPα protein and the human IL-15 protein, and (ii) comprises human intraepithelial lymphocytes (IELs) in the lung or small intestine and Peyer's patches of the genetically modified mouse,
wherein the genetically modified mouse is immunodeficient and comprises a Rag2 gene knock-out and an IL2rg gene knock-out, a Rag2 gene knock-out, or an IL2rg gene knock-out.
15. The engraftment model according to claim 14 , wherein the null mutation is a deletion of at least mouse SIRPα exons 2-4, wherein the genetically modified mouse is heterozygous for the allele comprising the nucleic acid sequence that encodes the human SIRPα protein.
16. The engraftment model according to claim 14 , wherein the null mutation is a deletion of at least mouse SIRPα exons 2-4, wherein the genetically modified mouse is homozygous for the allele comprising the nucleic acid sequence that encodes the human SIRPα protein.
17. The engraftment model according to claim 14 , wherein the human SIRPα protein is a functional fragment of a full length human SIRPα protein and the human IL-15 protein is a functional fragment of a full-length human IL-15 protein.
18. The engraftment model according to claim 17 , wherein the functional fragment comprises an extracellular domain of human SIRPα.
19. The engraftment model according to claim 14 , wherein the null mutation is a deletion of at least mouse IL-15 exons 5-8, wherein the genetically modified mouse is heterozygous for the allele comprising the nucleic acid sequence that encodes the human IL-15 protein.
20. The engraftment model according to claim 14 , wherein the null mutation is a deletion of at least mouse IL-15 exons 5-8, wherein the genetically modified mouse is homozygous for the allele comprising the nucleic acid sequence that encodes the human IL-15 protein.